Polycystic Kidney Disease (PKD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years
Polycystic kidney disease (PKD) is a genetic disorder that primarily affects kidneys. It causes fluid-filled cysts to grow inside the kidneys, which increase the size and damage tissues of the kidneys. Symptoms of the disease include abdomen and back pain, urinary tract infection, frequent urination, blood in urine, kidney stones, and others. There are mainly two types of PKD: autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD). The main reason for the disease is spontaneous mutation in PKD1, PKD2, and PKHD1 genes. These genes encode protein products polycystin-1 (PC1) and polycystin-2 (PC2 or TRPP2) that are responsible for normal kidney development, function, and organization. Therefore, mutation in these genes can lead to PKD.
Download the sample report at: https://www.pharmaproff.com/request-sample/1245
The diagnosis of the disease can be done through abdominal computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI) scan, and intravenous pyelogram. Current line of treatment for PKD focuses on treating the symptoms and avoiding complications. Some of the treatment options include blood pressure medications, antibiotics to treat urinary tract infections (UTIs), surgery to drain cysts and help relieve discomfort, low sodium diet, and diuretics.
In addition, Jynarque, developed by Otsuka Holdings Co. Ltd., is the first U.S. Food and Drug Administration (USFDA) approved drug for the treatment of patients with rapidly progressing APKD, the most common form of PKD.
Get the detailed analysis at: https://www.pharmaproff.com/report/polycystic-kidney-disease-therapeutics-pipeline-analysis
According to the research, many drugs being developed for PKD are to be administered orally. It has been found that oral route of administration is easy to use, cost-effective, and convenient.
Companies that are involved in developing therapeutics for PKD have shown positive clinical results in the various phases of drug development. For instance, in January 2019, Reata Pharmaceuticals Incorporated announced the completion of phase II study, and start of phase III trial of bardoxolone for ADPKD.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1245
It has been observed that many pharmaceutical companies are developing new and improved technologies and going into partnerships or acquiring other companies for the development of PKD therapeutics. For instance, in September 2018, Otsuka Holdings Co. Ltd. acquired Visterra Inc. to expand its portfolio and to develop better therapeutics for PKD.
Otsuka Holdings Co. Ltd., Exelixis Incorporated, Palladio Biosciences, XORTX Pharma Corp., Reata Pharmaceuticals Inc., and others are involved in the development of therapeutics for PKD.
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PKD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PKD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to PKD.